Arcturus Therapeutics Holdings Inc.
ARCT evidence brief
What we can confirm
- BioSniper Score:
- 8.9 / 10
- Market Cap:
- $444.3M
- Lead Asset:
- ARCT-032 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ARCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARCT
Arcturus Therapeutics Holdings Inc. (ARCT) is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics, with a lead pipeline including ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis, and a partnered COVID-19 vaccine (Kostaive/ARCT-154) approved in some markets.
Key risk: Revenue insufficient to cover costs
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$444.3M
Cash Runway
—
Lead Asset
ARCT-032 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 6 clinical trials for Arcturus Therapeutics Holdings Inc..
Arcturus Therapeutics Holdings Inc. (ARCT) is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics, with a lead pipeline including ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis, and a partnered COVID-19 vaccine (Kostaive/ARCT-154) approved in some markets.
- Cash & equivalents of $191.5M as of 2026-06-30 [sec].
- Total revenue of $3.0M and net income of -$23.8M for the quarter ended June 30, 2026 [sec].
- Encouraging interim Phase 2 results for ARCT-810 in OTC deficiency announced September 23, 2026 [news · published 2026-09-23].
- Introduced LUNAR 2.0™ next-generation mRNA delivery platform on September 23, 2026 [news · published 2026-09-23].
- ARCT-032 (cystic fibrosis) is in Phase 2 with Orphan Drug status and partnered with the Cystic Fibrosis Foundation [pipeline].
What works
- Cash runway to 2028 provides financial flexibility for pipeline advancement [news · published 2026-02-12].
- ARCT-810 Phase 2 interim results are encouraging, supporting the OTC deficiency program [news · published 2026-09-23].
- LUNAR 2.0 platform introduction may enhance delivery capabilities for liver and respiratory therapeutics [news · published 2026-09-23].
- ARCT-032 holds Orphan Drug designation and is supported by the Cystic Fibrosis Foundation [pipeline].
What to weigh
- Net loss of $23.8M in the latest quarter with only $3.0M in revenue, indicating ongoing cash burn [sec].
- ARCT-154 (COVID-19 vaccine) faces intense competition from 54 other candidates [pipeline].
- Pipeline candidates (ARCT-810, ARCT-032) are still in Phase 2, with no approved products generating significant revenue yet [pipeline].
- Forward-looking statements caution about risks and uncertainties in pipeline success and enrollment timelines [news · published 2026-08-06].
From the filings
Quoted directly from source documents.
Encouraging interim Phase 2 results for ARCT-810
“today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency”
News · September 23, 2026
Introduction of LUNAR 2.0 platform
“introduced LUNAR 2.0™, the Company’s next-generation mRNA delivery platform”
News · September 23, 2026
Risks & what to watch (4)›
Key risks
- Revenue insufficient to cover costs — Revenue of $3.0M vs net loss of $23.8M in Q2 2026, indicating heavy cash burn [sec].
- Pipeline still in Phase 2 — Lead candidates ARCT-810 and ARCT-032 are in Phase 2, no approved products generating revenue [pipeline].
- Intense competition for COVID vaccine — ARCT-154 faces 54 competitors including Pfizer/BioNTech and Valneva [pipeline].
- Forward-looking statement risks — Company cautions about risks in pipeline success and enrollment timelines [news · published 2026-08-06].
What to watch
- Phase 2 data for ARCT-810 (OTC deficiency) and ARCT-032 (cystic fibrosis) [news · published 2026-09-23].
- Enrollment progress for ARCT-032 Phase 2 study [news · published 2026-08-06].
- Cash runway and burn rate updates in future financial reports [sec].
- Regulatory developments for Kostaive/ARCT-154 in additional markets [pipeline].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Arcturus Therapeutics Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Arcturus Therapeutics Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.31 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 28.2%
- Days to cover
- 15.5
- Shares short
- 6,441,740
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Arcturus Therapeutics Holdings Inc.?
Arcturus Therapeutics Holdings Inc. (ARCT) is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics, with a lead pipeline including ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis, and a partnered COVID-19 vaccine (Kostaive/ARCT-154) approved in some markets.
What is Arcturus Therapeutics Holdings Inc.'s lead drug candidate?
Arcturus Therapeutics Holdings Inc.'s most advanced tracked candidate is ARCT-032 (Phase 2) for Cystic Fibrosis.
Who is the CEO of Arcturus Therapeutics Holdings Inc.?
Mr. Joseph E. Payne M.Sc. is the chief executive officer of Arcturus Therapeutics Holdings Inc. (ARCT).
Where is Arcturus Therapeutics Holdings Inc. headquartered?
Arcturus Therapeutics Holdings Inc. (ARCT) is headquartered in San Diego, CA, United States.
What therapeutic areas does Arcturus Therapeutics Holdings Inc. focus on?
Arcturus Therapeutics Holdings Inc. develops therapies across Oncology, Rare Disease, Immunology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.